Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jun;7(Suppl 2):S57-S62.
doi: 10.21037/cdt.2016.11.21.

Shifting paradigms for treatment of symptomatic aortic stenosis in lower risk populations: role of a newer generation balloon-expandable transcatheter aortic valve implantation device

Erik Walter Holy  1 , Mohamed Abdel-Wahab  1
Affiliations
Editorial

Shifting paradigms for treatment of symptomatic aortic stenosis in lower risk populations: role of a newer generation balloon-expandable transcatheter aortic valve implantation device

Erik Walter Holy et al. Cardiovasc Diagn Ther. 2017 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Abdel-Wahab reports receiving institutional research grants from St. Jude Medical and Biotronik and lecture fees from Medtronic and Boston Scientific. Dr. Abdel-Wahab is a proctor for Boston Scientific. Dr. Holy is currently supported by an EAPCI training grant sponsored by Edwards Lifesciences and a research grant from the “Walter and Gertrud Siegenthaler” Foundation of the University of Zurich, Switzerland.

Figures

Figure 1
Figure 1
Aortic root angiogram during implantation of a Sapien XT (A and C) and the newer generation Sapien 3 (B and D) transcatheter heart valve. Both heart valves comprise a balloon-expandable cobalt chromium frame and a trileaflet bovine pericardial tissue valve. While the Sapien XT is constituted only of a PET inner skirt, the inflow portion of the Sapien 3 transcatheter heart valve has an additional outer PET sealing skirt on top of the inner skirt which significantly reduces the extent of PVR. Blue arrow indicates position of the central marker of the S3 THV system at the level of the aortic annulus. PET, polyethylene terephthalate; THV, transcatheter heart valve.
Figure 2
Figure 2
Improved efficacy and safety profile of new generation TAVI devices: contributing factors. √√, important contribution; √, moderate contribution. PPM, patient prosthesis mismatch; PVR, paravalvular regurgitation.
See this image and copyright information in PMC

Comment on

References

    1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006-8. 10.1161/01.CIR.0000047200.36165.B8 - DOI - PubMed
    1. Webb JG, Chandavimol M, Thompson CR, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006;113:842-50. 10.1161/CIRCULATIONAHA.105.582882 - DOI - PubMed
    1. Vahl TP, Kodali SK, Leon MB. Transcatheter Aortic Valve Replacement 2016: A Modern-Day "Through the Looking-Glass" Adventure. J Am Coll Cardiol 2016;67:1472-87. 10.1016/j.jacc.2015.12.059 - DOI - PubMed
    1. Vahanian A, Urena M, Walther T, et al. Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial. EuroIntervention 2016;12:e235-43. 10.4244/EIJV12I2A37 - DOI - PubMed
    1. Wenaweser P, Stortecky S, Schwander S, et al. Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J 2013;34:1894-905. 10.1093/eurheartj/eht086 - DOI - PubMed

LinkOut - more resources